Published in Obesity and Diabetes Week, May 24th, 2004
"A total of 385 drug-therapy naive patients, with inadequately controlled type 2 diabetes, were randomized into a multinational, parallel-group study to compare two strategies for dose titration of the oral hypoglycemic agent repaglinide. Patients were allocated to either a fasting blood glucose (FBG) monitoring group with titration target 4.4-6.1 mmol/L or to a postprandial blood glucose (PPBG) monitoring group with titration target 4.4-8.0 mmol/L," an international team of scientists reports.
"An initial titration period of up to 8 weeks was followed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.